Abstract
Background and aims Up till now the role of simeprevir plasma concentrations has not been described in treated patients affected by chronic hepatitis C and with dermatological side-effects. In this study, we have evaluated a possible relationship between plasma levels and the onset of skin complaints for the first time. Methods We report a clinical and pharmacokinetic analysis of 56 patients treated with simeprevir-based therapies. Results Simeprevir plasma concentrations were significantly related to dermatological side-effects at early time-points (P < 0.001). In logistic regression, simeprevir concentrations at 1 week was the best predictive factor forskin symptoms (OR = 1.901, 95%IC: 1.001–2.304; P = 0.007). Conclusion Simeprevir plasma measurements could be a useful tool in a real-life clinical setting for prevention of dermatological symptoms.
Original language | English |
---|---|
Pages (from-to) | 705-708 |
Number of pages | 4 |
Journal | Digestive and Liver Disease |
Volume | 49 |
Issue number | 6 |
DOIs | |
Publication status | Published - Jun 2017 |
Externally published | Yes |
Keywords
- Dermatological side-effects
- HCV
- Pharmacokinetics
- Simeprevir
- Therapeutic drug monitoring